Who Supplies Gemcitabine to India from UNITED KINGDOM

To import finished pharmaceutical formulations containing Gemcitabine into India, the Central Drugs Standard Control Organization (CDSCO) mandates that the foreign manufacturer obtain an Import Registration Certificate and an Import License. The application process involves submitting comprehensive documentation, including the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process. For formulations under HS Code 30049049, the CDSCO requires that the product complies with the Indian Pharmacopoeia standards and provides evidence of safety, efficacy, and quality. Additionally, the Directorate General of Foreign Trade (DGFT) issues an Importer Exporter Code (IEC) to the Indian buyer, which is necessary for customs clearance and import transactions.

Upon arrival in India, finished pharmaceutical formulations containing Gemcitabine are subject to quality testing by CDSCO-approved laboratories. Each batch must undergo testing to verify its compliance with Indian Pharmacopoeia standards. The Certificate of Analysis (CoA) must accompany each shipment, detailing the product's composition, manufacturing process, and stability data. Stability studies should adhere to International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions, to ensure the product's efficacy and safety under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity of the documentation and the quality of the product. If a batch fails to meet the required standards, it may be rejected, leading to delays or additional costs for the importer.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products to enhance drug safety and efficacy. Notably, on April 8, 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Gemcitabine, must obtain an Import Registration Certificate and an Import License. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import landscape, encouraging domestic manufacturing and potentially reducing reliance on imports. However, bilateral agreements between India and the United Kingdom may provide certain concessions or streamlined procedures for pharmaceutical imports, subject to compliance with regulatory standards.

India imports finished Gemcitabine formulations primarily due to the demand for patented or branded products that are not manufactured domestically. Specific dosage forms, such as certain injection formulations, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, the import dependency arises from the need to meet diverse patient requirements and to access advanced formulations. The market size for Gemcitabine formulations in India is substantial, with imports contributing to a significant portion of the market share.

The import duty structure for finished pharmaceutical formulations containing Gemcitabine under HS Code 30049049 includes a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied on the total value, including the BCD and SWS. There are no specific exemptions or preferential rates for imports from the United Kingdom under the Most Favored Nation (MFN) status. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST, resulting in a significant cost addition to the imported product.

India sources finished Gemcitabine formulations from the United Kingdom due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. The United Kingdom's competitive advantage lies in its established patents, advanced manufacturing technologies, and a reputation for producing high-quality pharmaceutical products. Other suppliers, such as China, Germany, and the United States, also contribute to India's Gemcitabine import market. However, the United Kingdom's share remains significant due to these competitive factors.

India imports finished Gemcitabine formulations from the United Kingdom due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. The United Kingdom's adherence to international quality standards and its established reputation in pharmaceutical manufacturing make it a preferred source for these formulations.

When compared to other origins such as China, the European Union, and the United States, the United Kingdom offers competitive advantages in terms of quality, regulatory compliance, and reliability. While other countries may offer lower prices, the United Kingdom's products are often perceived as higher quality, with better regulatory oversight and consistency in manufacturing practices.

Indian importers face several supply chain risks when sourcing finished Gemcitabine formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory delays, highlighting the importance of risk management strategies.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate the risk of supply disruptions.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential delays.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risk.
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with market demand to optimize inventory costs.